Serum cytokine profile during Mycobacterium ulcerans infection (Buruli ulcer)

International Journal of Dermatology

Volumn 49, Issue 11, 2010, Pages 1297-1302

  Zavattaro, Elisa ^a   Mesturini, Riccardo ^b,c   Dossou, Ange ^d   Melensi, Matteo ^b,c   Johnson, Roch Christian ^e   Sopoh, Ghislain ^d   Dianzani, Umberto ^b,c   Leigheb, Giorgio ^a,c  

^a Department of Clinical and Experimental Medicine ^*  (Italy)

^b Immunology Unit   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d Centre de Dépistage et de Traitement de l Ulcère de Buruli CDTUB   (Benin)

^e Ministere de la Sante Publique   (Benin)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 7; RIFAMPICIN; STREPTOMYCIN; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BURULI ULCER; CHILD; CLINICAL ARTICLE; CYTOFLUOROMETRY; FEMALE; HELPER CELL; HUMAN; INFANT; MALE; MYCOBACTERIUM ULCERANS; PROTEIN BLOOD LEVEL; SCHOOL CHILD;

ADOLESCENT; ADULT; CHILD; FEMALE; HUMANS; INFANT; INTERFERON-GAMMA; INTERLEUKINS; MALE; MYCOBACTERIUM INFECTIONS; MYCOBACTERIUM ULCERANS; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77958566760     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04615.x     Document Type: Article

References (25)

1. Van Der Werf TS, Stienstra Y, Johnson RC, et al. Mycobacterium ulcerans disease. Bull World Health Organ 2005; 83: 785-791.
2. Wansbrough-Jones M, Phillips R. Buruli ulcer: emerging from obscurity. Lancet 2006; 367: 1849-1858.
3. Senior K. Buruli ulcer: dare we continue to ignore it? Lancet Infect Dis 2009; 9: 273.
4. George KM, Pascopella L, Welty DM, et al. A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun 2000; 68: 877-883.
5. Dobos KM, Small PL, Deslauriers M, et al. Mycobacterium ulcerans cytotoxicity in an adipose cell model. Infect Immun 2001; 69: 7182-7186.
6. WHO. Report of the 2008 Technical Advisory Group (TAG) Meeting on Buruli ulcer. Available at:
7. Gooding TM, Johnson PD, Campbell DE, et al. Immune response to infection with Mycobacterium ulcerans. Infect Immun 2001; 69: 1704-1707.
8. Gooding TM, Johnson PD, Smith M, et al. Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infect Immun 2002; 70: 5562-5567.
9. Gooding TM, Kemp AS, Robins-Browne RM, et al. Acquired T-helper 1 lymphocyte anergy following infection with Mycobacterium ulcerans. Clin Infect Dis 2003; 36: 1076-1077.
10. Prevot G, Bourreau E, Pascalis H, et al. Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease. Infect Immun 2004; 72: 958-965.
11. Westenbrink BD, Stienstra Y, Huitema MG, et al. Cytokine responses to stimulation of whole blood from patients with Buruli ulcer disease in Ghana. Clin Diagn Lab Immunol 2005; 12: 125-129.
12. Phillips R, Horsfield C, Kuijper S, et al. Cytokine response to antigen stimulation of whole blood from patients with Mycobacterium ulcerans disease compared to that from patients with tuberculosis. Clin Vaccine Immunol 2006; 13: 253-257.
13. Asiedu KSR, Raviglione M. Buruli Ulcer: Mycobacterium Ulcerans Infection. World Health Organization 2000. Available at:
14. WHO. Report of the 2007 Technical Advisory Group (TAG) Meeting on Buruli Ulcer. Available at:
15. World Health Organization. Global Buruli Ulcer Initiative: provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli Ulcer) 2004. Available at:
16. WHO. Global Buruli Ulcer Initiative. Available at:
17. Flynn JL, Chan J, Triebold KJ, et al. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178: 2249-2254.
18. Lienhardt C, Azzurri A, Amedei A, et al. Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. Eur J Immunol 2002; 32: 1605-1613.
19. Jo EK, Park JK, Dockrell HM. Dynamics of cytokine generation in patients with active pulmonary tuberculosis. Curr Opin Infect Dis 2003; 16: 205-210.
20. Yeboah-Manu D, Peduzzi E, Mensah-Quainoo E, et al. Systemic suppression of interferon-gamma responses in Buruli ulcer patients resolves after surgical excision of the lesions caused by the extracellular pathogen Mycobacterium ulcerans. J Leukoc Biol 2006; 79: 1150-1156.
21. Sarfo FS, Phillips RO, Ampadu E, et al. Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans. Clin Vaccine Immunol 2009; 16: 61-65.
22. Phillips R, Sarfo FS, Guenin-Macé L, et al. Immunosoppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with Buruli ulcer disease. J Infect Dis 2009; 200: 1675-1684.
23. Kiszewski AE, Becerril E, Aguilar LD, et al. The local immune response in ulcerative lesions of Buruli disease. Clin Exp Immunol 2006; 143: 445-451.
24. Schipper HS, Rutgers B, Huitema MG, et al. Systemic and local interferon-gamma production following Mycobacterium ulcerans infection. Clin Exp Immunol 2007; 150: 451-459.
25. Peduzzi E, Groeper C, Schutte D, et al. Local activation of the innate immune system in Buruli ulcer lesions. J Invest Dermatol 2007; 127: 638-645.